Share Name Share Symbol Market Type Share ISIN Share Description
Intelligent Ultrasound Group Plc LSE:MED London Ordinary Share GB00BN791Q39 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 9.50 1,348 08:00:00
Bid Price Offer Price High Price Low Price Open Price
9.00 10.00 9.50 9.50 9.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 5.31 -3.62 -3.59 21
Last Trade Time Trade Type Trade Size Trade Price Currency
10:42:53 O 1,348 9.20 GBX

Intelligent Ultrasound (MED) Latest News

More Intelligent Ultrasound News
Intelligent Ultrasound Takeover Rumours

Intelligent Ultrasound (MED) Share Charts

1 Year Intelligent Ultrasound Chart

1 Year Intelligent Ultrasound Chart

1 Month Intelligent Ultrasound Chart

1 Month Intelligent Ultrasound Chart

Intraday Intelligent Ultrasound Chart

Intraday Intelligent Ultrasound Chart

Intelligent Ultrasound (MED) Discussions and Chat

Intelligent Ultrasound Forums and Chat

Date Time Title Posts
17/10/201912:27Medaphor Group PLC 79
10/7/201906:57MEDAPHOR thread9
24/10/201214:08MicroEmissive Displays - LCD Replacement Technology !787
01/12/200410:57MicroEmissve Displays - LCD Replacement Technology !-
12/2/200312:42media stocks armageddon1

Add a New Thread

Intelligent Ultrasound (MED) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-11-21 10:42:539.201,348124.02O
View all Intelligent Ultrasound trades in real-time

Intelligent Ultrasound (MED) Top Chat Posts

Intelligent Ultrasound Daily Update: Intelligent Ultrasound Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker MED. The last closing price for Intelligent Ultrasound was 9.50p.
Intelligent Ultrasound Group Plc has a 4 week average price of 9p and a 12 week average price of 9p.
The 1 year high share price is 19.50p while the 1 year low share price is currently 4.93p.
There are currently 219,996,792 shares in issue and the average daily traded volume is 7,889 shares. The market capitalisation of Intelligent Ultrasound Group Plc is £20,899,695.24.
tullynessle: Another Non-Regulatory RNS today Medaphor Group PLC AI database exceeds 1 million images 27 November 2018 MedaPhor Group plc ("MedaPhor" or the "Company") MedaPhor's AI obstetric image database exceeds 1 million images MedaPhor, the intelligent ultrasound software and simulation company, is pleased to announce that its database used for training its artificial intelligence (AI) products now exceeds 1 million obstetric ultrasound images. Large image libraries are a prerequisite to creating AI solutions. These images have helped MedaPhor to develop its ScanNav(R) AI-based clinical software for ultrasound professionals. The one million mark is a significant milestone for the Company, as it will enable it to build on its ScanNav software for the global obstetric ultrasound market. MedaPhor's ScanNav intelligent ultrasound technology, which uses AI algorithms and deep learning techniques to automatically assess ultrasound images, is currently being piloted in UK hospitals to support sonographers carrying out the 20 week anatomy scan. ScanNav assists sonographers to ensure that the images they are taking conform to the UK Fetal Anomaly Screening Programme (FASP) protocol. In future, the software will also be capable of automatically recording required images during the ultrasound scan. Continued.........
tullynessle: RNS Non-Regulatory today. Medaphor Group PLC MedaPhor commences clinical trial for AnatomyGuide 23/11/2018 3:56pm RNS Non-Regulatory MedaPhor commences clinical trial for AnatomyGuide MedaPhor (AIM:MED), the intelligent ultrasound software and simulation company, announces it is commencing a clinical trial within the Aneurin Bevan University Health Board to capture data for its AnatomyGuide artificial intelligence (AI) software for ultrasound-guided anaesthetic procedures such as peripheral nerve blocks. Increasingly, ultrasound-guided peripheral nerve blocks are being used as a safer and more cost-effective alternative to general anaesthesia but not all anaesthetists have the specialist knowledge of ultrasound anatomy to perform them. AnatomyGuide provides software support and guidance to aid less experienced clinicians during the procedure. Using deep-learning techniques on a data set of thousands of real-patient images, the technology is 'taught' to recognise key anatomical structures. Then, by highlighting these structures in real-time during an ultrasound-guided nerve block procedure, AnatomyGuide's AI makes it easier for clinicians to accurately target the nerve. The clinical data from the Aneurin Bevan clinical trial is expected to complete the required data set. Through the adoption of AnatomyGuide, it is hoped that hospitals will be able to increase the number of ultrasound-guided nerve blocks that they can perform. Principal Investigator and consultant anaesthetist, Dr David Burckett-St.Laurent, said: "AnatomyGuide will help tip the balance of safety and confidence in favour of performing regional anaesthesia. I feel privileged to work with a Welsh company that is leading the world in developing AI-based ultrasound software. Our aim is to make a real clinical difference to patients by increasing the availability of regional anaesthesia through cutting edge technology. It is very exciting." AnatomyGuide is being developed as part of an Innovate UK project funded within the government's AI and data grand challenge. Nicholas Sleep, CTO at MedaPhor, commented: "AnatomyGuide shows how strategic government investment can catalyse an innovative technology that we hope will make a real difference to NHS patient care. The team in Cardiff are excited to be working with Innovate UK in developing AI technology that has real-world applications and we look forward to completing the clinical trials with David and the Aneurin Bevan University Health Board."
wild bill: From the Scotsman this morning MED calls in administrators – and more technology failures feared A SCOTS company credited with developing the world's smallest television screen has become the latest victim of the global economic crisis, prompting fears that there could be a wave of business failures in the technology sector. MicroEmissive Displays is to appoint an administrator after failing to find funding to support its pioneering business. The Edinburgh-based firm, led by chief executive Bill Miller, said yesterday it had been hit by the "severe slowdown" in the demand for consumer electronics – and had been unable to borrow enough cash to survive . MED, which has about 50 staff – evenly split between its operations in Scotland and Dresden, Germany – is continuing to trade and has not yet made any staffing cuts as a result of yesterday's announcement. In June it said it was to cut five jobs after issuing a profit warning, saying monthly profitability would be delayed until 2009. Last night technology entrepreneur and investor Ian Ritchie said he believed that , following the collapse, other struggling firms in the sector could suffer a similar fate. He said: "I think it is very likely that a lot more technology companies will fold, like in the dot com bust in 2001, when a lot of good companies were wiped out. "MicroEmissives is quite a big one and people will feel that it has gone, but there will be a lot of good smaller technology companies which will go missing without anyone noticing." Ritchie, a former board member of Scottish Enterprise, added: "It is a real shame that MicroEmissives is to go into administration. It is not a good time to be looking for emergency cash because it is just not around." The firm, listed on the Alternative Investment Market, suspended its shares following yesterday's announcement. The price before the suspension was 0.45p. A spin-out of Edinburgh and Napier universities, the company warned in September that if it did not find new financing it would run out of cash by mid-December. Last month it reported a loss of £3.8 million for the six months to 30 June – an increase of £700,000 over the first half of 2007. The news is the latest in a string of blows for Scotland's technology sector. Fellow university spin-out Wolfson is battling with a plunging share price and the departure of its chief executive Dave Shrigley, as well as the loss of most of its business with iPod maker Apple. Earlier this year, listed biotech firm Ardana and dental technology company Idmos both fell into administration after a period of poor trading, while in February, Stem Cell Sciences said it was closing its headquarters in the Scottish capital in favour of its facilities in Cambridge. Adrian Smith, programme director with the Edinburgh Pre-Incubator Scheme at the University of Edinburgh, added: "I understand they have always had a problem shifting product. It's a shame because there are a lot of able people there and with a bit of luck they'll come through it, something will happen. It's discouraging for other people if they see companies having a hard time on a public market." A spokesman for MicroEmissives said the company would issue another statement once an administrator was appointed.
gninraw: The board of directors still managed to take a 7% pay rise, and the CEO took a £30000 pay rise in the last 9 months. Wonder how they managed to justify that? If they are openly saying that there "can be no certainty that a transaction will occur", then my guess is that a deal has already been done, and this is designed to trash the share price even further so that a "last minute" rescue plan seems fantastic to share holders who will welcome it with open arms......, and at a rock bottom price. Believe me when I say that these people are self serving and don't give a cr*p about share holders.
puffin tickler: According to the Finance page on Yahoo, MED currently has a market cap of £1.04m. Why would they need so much cash for a management buyout? If management want to buy the company having completely trashed the share price they will need to have the decency to pay a healthy multiple to get people to sell.
thecurrymonster: Am I the only one excited about this little gem. I think so... I got excited about them around three years ago, and I kept a close eye on the company - lots of placings and fundraisings, lots of production problems and lot's of other problems. The production problems started getting sorted about 18 months ago, and I started buying around that time, with a 12 month boom-or-bust timeframe - this was also my pick on the share comp over on TMF and one way or another, I ended up buying a lot more of these than I ever intended to! I did OK with this last year, and I top-sliced most of my holdings at over 50p - mainlybecause the share price had risen on the news of the successes of the Dresden facility rather than any definite large orders - top slicing is rarely a bad strategy anyway and as it turns out, I got lucky. I finally sold the remainder of my holding somewhere around 30p, which was around about my average buy price. Even now, the orders haven't materialised, and I'm not convinced that they ever will now - it's taken so long, that any competitive advantage must now be seriously in doubt - after all, if a company the size of Samsung SDI wants to produce microscreens then they are not going to let a tiny Scottish company get in there way, patents or no patents - quite a lot of the intellectual property belongs to Cambridge Display Technology anyway. Raising further funding in todays environment is going to be challenging unless there are big orders in the pipeline, so it looks like a buy-out of some sort is the only hope, and I can't see this coming at much of a premium to the shareprice either, so I'm not investing. I would love to see this compayt succeed and good luck to the remaining shareholders - it's still on my radar, but without any serious orders, I'm staying clear of this for now.
chocaholic: Ok, now I'm really confused. MED have recently announced that they have signed 2 MOUs. On 2 July and on 11 July Yet on 2 July AXA reduced their holding from 6.425m to 2.33m shares and the share price has dropped from 14p to 8.5p. I would assume that these are the result of "discussions underway with a variety of potential customers" which "will result in significant volume orders" referred to in the Annual Report and that they are confirmation that we are on the way to month-on-month profitability during the next financial year. Obviously AXA don't share my optimism.
friars3: (1) Is it possible to find out who the major customers are, (2) When will the product be on the shelves. (3) WHAT COMPANYS ARE USING THE MICROMISSIVE EYE SET. (4) THE LATEST DEVELOPMENT WITH THE PROCUCT. THE MANAGMENT SEEM TO BE SPENDING, MOST OF THERE TIME ON THE LECTURE CIRCUIT, with little productivity from it, spending our money THE COMPANY MUST GIVE US POSITIVE NEWS keep us up dated reguarly I recall the site visit to: Dresden, Germany on the 26 July 2007, It didn't do a thing for the share price. Those selected clients had a good night out. At our expence. REMEMBER Investor Site Visit (Microemissive) RNS Number:8807A MicroEmissive Displays Group PLC 26 July 2007 For immediate release: 26 July 2007 MicroEmissive Displays Group plc ("MED" or "the Company") Investor Site Visit MED (AIM: MED.L), the AIM listed designer and manufacturer of low-power light emitting polymer displays, today announces that it is hosting a site visit for certain institutional investors at its new volume manufacturing facility in Dresden, Germany. No new material information will be disclosed during the visit. For further information, please visit or contact:
thecurrymonster: I've sold the last of my stock over the past couple of weeks or so - I'm ready to jump back in if I see a good reason to, but it seems like it is jam tomorrow with this one - there have still been no real announcements of volume orders, and without these, the company is going nowhere. It now seems that the institutions are bailing as well, and with the amount of institutional holdings here, it wouldn't take much dumping of stock to completely trash the share price. I am no longer comfortable holding this, and there are better homes for the cash in the short term IMHO. Good luck to those that still hold, I'll still be around, and MED is very much still on my RADAR - I will buy back in when there is some good news to support the share price.
unionhall: If I am reading this correctly the options require an 80% share price uplift in three years for partial exercising (30%) and 170% share price uplift for complete exercising. That certainly is a good incentive.... "The Ordinary Shares subject to LTIP awards will become exercisable in three years time subject to their continued employment and the satisfaction of share price targets (30% of the Ordinary Shares subject to LTIP awards will become exercisable if the Company's share price reaches at least #0.92 for a period of 90 trading days (30 of which must be consecutive days) during the three year period, with 100% becoming exercisable if the Company's share price reaches at least #1.38 for a period of 90 trading days (30 of which must be consecutive) during the three year period."
Intelligent Ultrasound share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191122 04:45:15